APRE vs. AKTX, ELYM, ESLA, XLO, LVTX, LTRN, SCLX, RNTX, BRNS, and MDCX
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Akari Therapeutics (AKTX), Eliem Therapeutics (ELYM), Estrella Immunopharma (ESLA), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Scilex (SCLX), Rein Therapeutics (RNTX), Barinthus Biotherapeutics (BRNS), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs. Its Competitors
Akari Therapeutics (NASDAQ:AKTX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
Akari Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Aprea Therapeutics' return on equity of -68.39% beat Akari Therapeutics' return on equity.
5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 38.1% of Akari Therapeutics shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Akari Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Aprea Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 811.76%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Akari Therapeutics.
Aprea Therapeutics has higher revenue and earnings than Akari Therapeutics.
In the previous week, Aprea Therapeutics had 4 more articles in the media than Akari Therapeutics. MarketBeat recorded 6 mentions for Aprea Therapeutics and 2 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.82 beat Aprea Therapeutics' score of 0.35 indicating that Akari Therapeutics is being referred to more favorably in the media.
Summary
Aprea Therapeutics beats Akari Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 7/2/2025 by MarketBeat.com Staff
